UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/700/0.1/18.06.25

UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/700/0.1/18.06.25 Stock

DE000HD21V08

Real-time Boerse Frankfurt Warrants 13:34:05 2024-06-28 EDT
0.7 ^EUR	-1.41%

Current month	+20.69%
1 month	+37.25%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/700/0.1/18.06.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

Verve Therapeutics, Inc. Announces Board Appointments	06-28	CI
Redburn Atlantic Initiates Vertex Pharmaceuticals at Buy With $545 Price Target	06-27	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $500 From $456, Maintains Overweight Rating	06-25	MT
Wells Fargo Adjusts Price Target on Vertex Pharmaceuticals to $555 From $540	06-24	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-28	0.7	-1.41%
24-06-27	0.71	+1.43%
24-06-26	0.7	+1.45%
24-06-25	0.69	-9.21%
24-06-24	0.76	+11.76%

Real-time Boerse Frankfurt Warrants

Last update June 28, 2024 at 01:34 pm

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	UniCredit
WKN	HD21V0
ISIN	DE000HD21V08
Date issued	2024-01-23
Strike	700 $
Maturity	2025-06-18 (353 Days)
Parity	10 : 1
Emission price	1.33 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1.22 €
Lowest since issue	0.07 €
Spread	0.38 €
Spread %	45.24%

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company